Frontlight ResearchEarly access
Colorectal cancer trials in China
616 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
- Where
- Harbin, Shenyang
- Age
- 18 years and over
- People
- 94
- Run by
- JiaRay Group
See details and how to joinNCT06783569 - Phase 2Not yet taking people in ChinaQL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer
- Where
- Jinan
- Age
- 18 years to 75 years
- People
- 21
- Run by
- Qilu Hospital of Shandong University
See details and how to joinNCT07156682 - Phase 2Taking peoplePucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 68
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06770270 - Phase 2Taking peoplePhase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
- Where
- Anyang, Fuzhou, Jinan, Kunming, Shanghai
- Age
- 18 years to 75 years
- People
- 138
- Run by
- Fudan University
See details and how to joinNCT07154316 - Phase 4Not yet taking people in ChinaThe Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer
- Where
- Qingdao
- Age
- 18 years to 70 years
- People
- 238
- Run by
- The Affiliated Hospital of Qingdao University
See details and how to joinNCT07152886 - Phase 2Taking peopleSCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 55
- Run by
- Ruijin Hospital
See details and how to joinNCT05576480 - No phaseNot yet taking people in ChinaLow Powered Colorectal Anastomosis After Rectal Excision (OASIS)
- Where
- Shanghai
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Bordeaux Colorectal Institute
See details and how to joinNCT07146334 - Phase 2Taking peopleOral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 57
- Run by
- Sun Yat-sen University
See details and how to joinNCT06764680 - No phaseNot yet taking people in ChinaThe Intraoperative Technical Errors of Robotic vs. Laparoscopic Radical Right Hemiclectomy
- Where
- Shandong
- Age
- 18 years to 80 years
- People
- 368
- Run by
- The Affiliated Hospital of Qingdao University
See details and how to joinNCT07138859 - Phase 1Taking peopleA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- Where
- Zhengzhou
- Age
- 18 years to 75 years
- People
- 21
- Run by
- GONGCHU Biotechnology Co., Ltd
See details and how to joinNCT06508307 - Phase 2/3Not yet taking people in ChinaNeoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 180
- Run by
- Changhai Hospital
See details and how to joinNCT07134218 - Phase 3Not yet taking people in ChinaNeoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
- Where
- Nanning
- Age
- 18 years to 75 years
- People
- 94
- Run by
- First Affiliated Hospital of Guangxi Medical University
See details and how to joinNCT07132008 - Phase 2Taking peopleA Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
- Where
- Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hengshui, Kunming, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Wuhan, Wuxi, Xiamen, Xi’an, Xiangyang, Yantai, Zhengzhou
- Age
- 18 years and over
- People
- 60
- Run by
- Shanghai Pharmaceuticals Holding Co., Ltd
See details and how to joinNCT06434597 - Phase 2Not yet taking people in ChinaA Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Sanjun Cai
See details and how to joinNCT07123441 - Phase 1/2Taking peopleTQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
- Where
- Beijing, Changchun, Changsha, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Wuhan, Wuxi, Xiamen, Xi’an, Xinyang, Yibin, Zhoukou
- Age
- 18 years to 75 years
- People
- 72
- Run by
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT07044908 - Phase 2Not yet taking people in ChinaRadiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
- Where
- Jinan
- Age
- 18 years to 75 years
- People
- 37
- Run by
- Jinan Central Hospital
See details and how to joinNCT07116577 - Phase 2Taking peopleNocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status
- Where
- Nanjing
- Age
- 18 years and over
- People
- 22
- Run by
- Sun Jing
See details and how to joinNCT06356714 - Phase 2/3Taking peopleNode-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 286
- Run by
- Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT06958419 - Phase 2Taking peopleSecond-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
- Where
- Shanghai
- People
- 119
- Run by
- Fudan University
See details and how to joinNCT06856187 - No phaseTaking peoplePatient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real World
- Where
- Chengdu
- Age
- 18 years and over
- People
- 300
- Run by
- West China Hospital
See details and how to joinNCT07105631 - No phaseEnrolling by invitationA Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics
- Where
- Beijing
- People
- 250
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07107815 - Phase 2Taking peopleEfficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 24
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07108127 - No phaseNot yet taking people in ChinaA Novel Oral Synbiotic Formula in Reducing Advanced Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers
- Where
- Hohhot
- Age
- 18 years to 90 years
- People
- 649 worldwide
- Run by
- Chinese University of Hong Kong
See details and how to joinNCT05592886 - Phase 1/2Not yet taking people in ChinaEfficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer
- Where
- Anyang, Shanghai
- Age
- 18 years and over
- People
- 20
- Run by
- Fudan University
See details and how to joinNCT07025850 - Phase 2/3Taking peopleFruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 84
- Run by
- Sun Yat-sen University
See details and how to joinNCT06441565